Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Neurocrine (NBIX) at Outperform, But Notes Post-Pandemic Headwinds to Achieving Guidance

February 11, 2022 8:09 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $69.00 price target on Neurocrine Bio. (NASDAQ: NBIX) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles